论文部分内容阅读
目的分析多发性骨髓瘤在BCD方案治疗中皮下和静脉注射硼替佐米的临床疗效差异。方法选取2010年5月-2015年3月在医院进行治疗的多发性骨髓瘤患者80例,均接受BCD方案(硼替佐米、地塞米松、环磷酰胺)治疗,将80例患者随机分为观察组和对照组各40例。观察组行皮下注射硼替佐米,对照组行静脉注射硼替佐米,比较2组患者的临床临床疗效和药物使用安全性。结果观察组患者治疗总有效率为90.0%,对照组治疗总有效率为87.5%,差异无统计学意义(P>0.05),观察组患者血小板减少Ⅲ级发生率和周围神经病变发生率均低于对照组,差异均有统计学意义(P<0.05);2组患者并发症发生率差异无统计学意义(P>0.05)。结论皮下和静脉注射硼替佐米在多发性骨髓瘤的BCD治疗效果上差异不大,皮下注射可以降低药物不良反应发生程度,利于患者康复。
Objective To analyze the clinical effects of subcutaneous and intravenous injection of bortezomib in patients with multiple myeloma undergoing BCD regimen. Methods Eighty patients with multiple myeloma treated in the hospital from May 2010 to March 2015 were enrolled in the BCD regimen (bortezomib, dexamethasone and cyclophosphamide), and 80 patients were randomly divided into Observation group and control group of 40 cases. The observation group received bortezomib subcutaneously and the control group received intravenous injection of bortezomib. The clinical efficacy and safety of drug use in the two groups were compared. Results The total effective rate was 90.0% in the observation group and 87.5% in the control group, with no significant difference (P> 0.05). The incidence of grade Ⅲ thrombocytopenia and peripheral neuropathy in the observation group were both low In the control group, the differences were statistically significant (P <0.05). There was no significant difference in the incidence of complications between the two groups (P> 0.05). Conclusion Bortezomib administered subcutaneously and intravenously has little effect on the treatment of BCD in multiple myeloma. Subcutaneous injection can reduce the incidence of adverse drug reactions and facilitate the recovery of patients.